US Patent 11253605 Codon-optimized CFTR MRNA
Patent 11253605 was granted and assigned to Translate Bio on February, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 23 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+253 characters)
Article
Patent abstract
The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Anusha Dias0
Brian Bettencourt0
Frank DeRosa0
Jonathan Abysalh0
Michael Heartlein0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
112536050
Date of Patent
February 22, 2022
0Patent Application Number
159071310
Date Filed
February 27, 2018
0Official Website
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 23 Feb, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11253605 Codon-optimized CFTR MRNA
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
11253605
Date of patent
February 22, 2022
Patent application number
15907131
Date Filed
February 27, 2018
Patent primary examiner
Find more entities like US Patent 11253605 Codon-optimized CFTR MRNA
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
